Regulatory Approval

    IVAX Corporation

      IVAX Receives Tentative Approval for Ciprofloxacin Tablets

IVAX Corporation (AMEX:IVX) (LSE:IVX.L) received tentative approval from the FDA
for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin Tablets USP,
in 100 mg, 250 mg, 500 mg and 750 mg strengths. Upon final approval, this
product will be sold through the company's wholly owned subsidiary, IVAX
Pharmaceuticals, Inc. Ciprofloxacin is the generic equivalent of Cipro(R), which
is an antibiotic marketed by the Bayer Corporation for the treatment of a broad
range of bacterial infections. U.S. sales of Cipro tablets in 100, 250, 500 and
750 mg dosage strengths were over $1.1 billion for the past twelve months ending
in the second quarter of 2003.

IVAX continues its aggressive program to increase the number of products in its
generic portfolio.

IVAX Corporation, headquartered in Miami, Florida, discovers, develops,
manufactures, and markets branded and brand equivalent (generic) pharmaceuticals
and veterinary products in the U.S. and internationally.

Copies of this and other news releases may be obtained free of charge from IVAX'
website at http://www.ivax.com.

The "FDA" refers to the United States Food and Drug Administration.

Except for the historical matters contained herein, statements in this press
release are forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements, involve risks and uncertainties which may
affect the company's business and prospects including the risks that final
approval of IVAX' ANDA for ciprofloxacin tablets in 100 mg, 250 mg, 500 mg, and
750 mg strengths may be delayed or not received at all; that launch of the
tablets may be delayed; changing market conditions; the availability and cost of
raw materials and other third party products; the impact of competitive products
and pricing; that IVAX may not increase the number of products in its generic
portfolio; and other risks and uncertainties based on economic, competitive,
governmental, technological and other factors discussed in the Company's Annual
Report on Form 10-K and its other filings with the Securities and Exchange
Commission. Cipro(R) is a registered trademark of the Bayer Corporation.